%0 Journal Article
%T The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial
%A Theodora C van Tilborg
%A Marinus JC Eijkemans
%A Joop SE Laven
%A Carolien AM Koks
%A Jan de Bruin
%A Gabrielle J Scheffer
%A Ron JT van Golde
%A Kathrin Fleischer
%A Annemieke Hoek
%A Annemiek W Nap
%A Walter KH Kuchenbecker
%A Petra A Manger
%A Egbert A Brinkhuis
%A Arne M van Heusden
%A Alexander V Sluijmer
%A Arie Verhoeff
%A Marcel HA van Hooff
%A Jaap Friederich
%A Jesper MJ Smeenk
%A Janet Kwee
%A Harold R Verhoeve
%A Cornelis B Lambalk
%A Frans M Helmerhorst
%A Fulco van der Veen
%A Ben Willem J Mol
%A Helen L Torrance
%A Frank JM Broekmans
%J BMC Women's Health
%D 2012
%I BioMed Central
%R 10.1186/1472-6874-12-29
%X Multicentre RCT in subfertile women indicated for a first IVF or intracytoplasmic sperm injection cycle, who are aged£¿<£¿44 years, have a regular menstrual cycle and no major abnormalities at transvaginal sonography. Women with polycystic ovary syndrome, endocrine or metabolic abnormalities and women undergoing IVF with oocyte donation, will not be included. Ovarian reserve will be assessed by measuring the antral follicle count. Women with a predicted poor response or hyperresponse will be randomised for a standard versus an individualised FSH regime (150 IU/day, 225-450 IU/day and 100 IU/day, respectively). Participants will undergo a maximum of three stimulation cycles during maximally 18 months. The primary study outcome is the cumulative ongoing pregnancy rate resulting in live birth achieved within 18 months after randomisation. Secondary outcomes are parameters for ovarian response, multiple pregnancies, number of cycles needed per live birth, total IU of FSH per stimulation cycle, and costs. All data will be analysed according to the intention-to-treat principle. Cost-effectiveness analysis will be performed to assess whether the health and associated economic benefits of individualised treatment of subfertile women outweigh the additional costs of an ORT.The results of this study will be integrated into a decision model that compares cost-effectiveness of the three dose-adjustment strategies to a standard dose strategy. The study outcomes will provide scientific foundation for national and international guidelines.NTR2657In vitro fertilisation (IVF) is the treatment of last resort for many subfertile couples and a very costly one, partly due to the use of expensive drugs, i.e. gonadotrophins, needed for controlled ovarian hyperstimulation (COH) [1]. COH is an essential part of IVF which is needed to obtain a reasonable yield of oocytes which can then be fertilised in vitro. In clinical practice physicians often rely on their clinical experience and judgement
%K Ovarian reserve
%K Antral follicle count
%K IVF
%K Individualised FSH stimulation dosages
%K Live birth rate
%U http://www.biomedcentral.com/1472-6874/12/29